Benchmarking whole exome sequencing in the German network for personalized medicine

Menzel, Michael and Martis-Thiele, Mihaela and Goldschmid, Hannah and Ott, Alexander and Romanovsky, Eva and Siemanowski-Hrach, Janna and Seillier, Lancelot and Bruechle, Nadina Ortiz and Maurer, Angela and Lehmann, Kjong-Van and Begemann, Matthias and Elbracht, Miriam and Meyer, Robert and Dintner, Sebastian and Claus, Rainer and Meier-Kolthoff, Jan P. and Blanc, Eric and Moebs, Markus and Joosten, Maria and Benary, Manuela and Basitta, Patrick and Hoelscher, Florian and Tischler, Verena and Gross, Thomas and Kutz, Oliver and Prause, Rebecca and William, Doreen and Horny, Kai and Goering, Wolfgang and Sivalingam, Sugirthan and Borkhardt, Arndt and Blank, Cornelia and Junk, Stefanie V. and Yasin, Layal and Moskalev, Evgeny A. and Carta, Maria Giulia and Ferrazzi, Fulvia and Toegel, Lars and Wolter, Steffen and Adam, Eugen and Matysiak, Uta and Rosenthal, Tessa and Doenitz, Juergen and Lehmann, Ulrich and Schmidt, Gunnar and Bartels, Stephan and Hofmann, Winfried and Hirsch, Steffen and Dikow, Nicola and Goebel, Kirsten and Banan, Rouzbeh and Hamelmann, Stefan and Fink, Annette and Ball, Markus and Neumann, Olaf and Rehker, Jan and Kloth, Michael and Murtagh, Justin and Hartmann, Nils and Jurmeister, Phillip and Mock, Andreas and Kumbrink, Joerg and Jung, Andreas and Mayr, Eva-Maria and Jacob, Anne and Trautmann, Marcel and Kirmse, Santina and Falkenberg, Kim and Ruckert, Christian and Hirsch, Daniela and Immel, Alexander and Dietmaier, Wolfgang and Haack, Tobias and Marienfeld, Ralf and Fuerstberger, Axel and Niewoehner, Jakob and Gerstenmaier, Uwe and Eberhardt, Timo and Greif, Philipp A. and Appenzeller, Silke and Maurus, Katja and Doll, Julia and Jelting, Yvonne and Jonigk, Danny and Maerkl, Bruno and Beule, Dieter and Horst, David and Wulf, Anna-Lena and Aust, Daniela and Werner, Martin and Reuter-Jessen, Kirsten and Stroebel, Philipp and Auber, Bernd and Sahm, Felix and Merkelbach-Bruse, Sabine and Siebolts, Udo and Roth, Wilfried and Lassmann, Silke and Klauschen, Frederick and Gaisa, Nadine T. and Weichert, Wilko and Evert, Matthias and Armeanu-Ebinger, Sorin and Ossowski, Stephan and Schroeder, Christopher and Schaaf, Christian P. and Malek, Nisar and Schirmacher, Peter and Kazdal, Daniel and Pfarr, Nicole and Budczies, Jan and Stenzinger, Albrecht (2024) Benchmarking whole exome sequencing in the German network for personalized medicine. EUROPEAN JOURNAL OF CANCER, 211: 114306. ISSN 0959-8049, 1879-0852

Full text not available from this repository. (Request a copy)

Abstract

Introduction: Whole Exome Sequencing (WES) has emerged as an efficient tool in clinical cancer diagnostics to broaden the scope from panel-based diagnostics to screening of all genes and enabling robust determination of complex biomarkers in a single analysis. Methods: To assess concordance, six formalin-fixed paraffin-embedded (FFPE) tissue specimens and four commercial reference standards were analyzed by WES as matched tumor-normal DNA at 21 NGS centers in Germany, each employing local wet-lab and bioinformatics. Somatic and germline variants, copy-number alterations (CNAs), and complex biomarkers were investigated. Somatic variant calling was performed in 494 diagnostically relevant cancer genes. The raw data were collected and re-analyzed with a central bioinformatic pipeline to separate wet- and dry-lab variability. Results: The mean positive percentage agreement (PPA) of somatic variant calling was 76 % while the positive predictive value (PPV) was 89 % in relation to a consensus list of variants found by at least five centers. Variant filtering was identified as the main cause for divergent variant calls. Adjusting filter criteria and re-analysis increased the PPA to 88 % for all and 97 % for the clinically relevant variants. CNA calls were concordant for 82 % of genomic regions. Homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI) status were concordant for 94 %, 93 %, and 93 % of calls, respectively. Variability of CNAs and complex biomarkers did not decrease considerably after harmonization of the bioinformatic processing and was hence attributed mainly to wet-lab differences. Conclusion: Continuous optimization of bioinformatic workflows and participating in round robin tests are recommended.

Item Type: Article
Uncontrolled Keywords: ; Whole exome sequencing; Molecular pathology; Multi-centric inter-laboratory test; Clinical exome; Precision oncology
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Pathologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 06 Aug 2025 06:05
Last Modified: 06 Aug 2025 06:05
URI: https://pred.uni-regensburg.de/id/eprint/65703

Actions (login required)

View Item View Item